骨髓病变对血液学毒性和[177Lu]Lu-PSMA-617治疗反应的影响:PSMA-PET/CT影像的启示
该回顾性研究纳入96例转移性去势抵抗性前列腺癌患者,评估治疗前PSMA-PET/CT骨病变范围、强度和异质性与[177Lu]Lu-PSMA-617治疗后血液学毒性、PSA反应和总生存的关系。广泛PSMA阳性骨受累与血液学毒性增加相关,PSMA摄取异质性越大PSA50反应率和总生存越低。
要点
- 19例(19.8%)发生临床显著血液学毒性。
- 因毒性停药者PSMA阳性骨体积占比中位数28% vs 1.7%(p=0.007)。
- PSMA摄取异质性高者PSA50反应率30.3% vs 64.5%(p=0.002)。
核心结论
- 广泛PSMA阳性骨受累与[177Lu]Lu-PSMA-617治疗的mCRPC患者血液学毒性增加相关。
- PSMA摄取异质性越大与PSA50反应率和总生存越低相关,但与血液学毒性无关。
- 作者认为需要仔细选择患者和监测,尤其是广泛骨病变者。
研究设计与样本
- 回顾性研究,纳入96例接受治疗前PSMA-PET/CT并接受标准治疗[177Lu]Lu-PSMA-617的mCRPC患者。
主要发现
- 19例(19.8%)发生临床显著血液学毒性。
- 因毒性停药者PSMA阳性骨体积占全身骨体积百分比中位数28% vs 1.7%(p=0.007)。
- 需要剂量延迟或减量者该百分比中位数21% vs 1.5%,需要输血者21% vs 1.4%,需要血小板输注者32% vs 1.8%(均p<0.01)。
- PSMA摄取异质性高者PSMA50反应率30.3% vs 64.5%(p=0.002)。
- PSMA低与PSMA高骨病变差异>50%与总生存显著缩短相关(p<0.001)。
临床怎么用
- 作者认为需要仔细选择患者和监测,尤其是广泛骨病变者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Despite the effectiveness of [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC), hematologic toxicity remains a concern, particularly in patients with bone metastases. This study evaluated whether the extent, intensity, and heterogeneity of bone disease on pretreatment PSMA-PET/CT were associated with hematologic toxicity, PSA response, and overall survival (OS) in mCRPC patients treated with [177Lu]Lu-PSMA-617. METHODS: This retrospective study included 96 mCRPC patients who underwent pretreatment PSMA-PET/CT and received standard-of-care [177Lu]Lu-PSMA-617. Hematologic toxicity, PSA responses, and OS were analyzed in relation to quantitative PET parameters, including tumor volume, SUVmean, and heterogeneity of PSMA uptake in bone metastases. RESULTS: Clinically significant hematologic toxicity occurred in 19 patients (19.8%). Treatment discontinuation was more likely in those with a significantly higher (p = 0.007) percentage of total bone volume with PSMA-avid disease (median 28% vs. 1.7%). Those requiring dose delays or reductions (median 21% vs. 1.5%), blood transfusions (median 21% vs. 1.4%), and platelet transfusions (median 32% vs. 1.8%) also exhibited higher median percentages of total bone volume involvement (all p < 0.01). Patients with more heterogeneous PSMA uptake had lower PSA50 response rates than those with more homogeneous uptake (30.3% vs. 64.5%, p = 0.002). A > 50% difference between PSMA-low and PSMA-high bone disease was associated with significantly shorter OS (p < 0.001). CONCLUSION: Extensive PSMA-avid bone involvement was associated with increased hematologic toxicity in mCRPC treated with [177Lu]Lu-PSMA-617. Greater heterogeneity in PSMA uptake correlated with lower PSA50 response and OS but not hematologic toxicity. Careful patient selection and monitoring are needed, particularly in those with widespread bone disease.
引用
- Borges N, Losee M, Liu M, et al. Effect of bone marrow disease on hematologic toxicity and response to [177Lu]Lu-PSMA-617 therapy: insights from PSMA-PET/CT imaging. Eur J Nucl Med Mol Imaging. 2025. PMID: 40908334. doi:10.1007/s00259-025-07541-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。